Premium
Long‐acting injectables good option for schizophrenia patients
Author(s) -
Canady Valerie A.
Publication year - 2019
Publication title -
mental health weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7583
pISSN - 1058-1103
DOI - 10.1002/mhw.31861
Subject(s) - tolerability , schizophrenia (object oriented programming) , retention rate , baseline (sea) , medicine , psychiatry , adverse effect , business , political science , marketing , law
A six‐month study evaluating the efficacy, safety and tolerability of two‐long‐acting injectable medicines has provided a favorable overall retention rate, and both medications reveal significant improvements from baseline in schizophrenia symptoms, according to officials at Alkermes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom